четверг, 6 января 2022 г.

together: “academic2.ru” plus 49 more

together: “academic2.ru” plus 49 more

Link to together

academic2.ru

Posted: 06 Jan 2022 02:32 PM PST

Android 12 Update Goes Live For The Samsung Galaxy S10 Lite together (RSS)

Posted: 06 Jan 2022 01:53 PM PST

Patterson Companies To Present At The 2022 J.P. Morgan Healthcare Conference

Posted: 06 Jan 2022 03:15 PM PST

Patterson Companies Inc. (Nasdaq: PDCO), a value-added distributor focused on providing best-in-class products, services, technology and experiences to the dental and animal health markets, announced today that the Company will present virtually at the 2022 J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 9:00 a.m. Eastern time.

The conference brings together leaders from across the healthcare industry, emerging fast-growth companies and innovative technology leaders, along with members of the investment community.

Patterson Companies' presentation will be available to download following the presentation by visiting www.pattersoncompanies.com, and clicking on "Investor Relations." A replay will also be available following the presentation.

About Patterson Companies Inc.

Patterson Companies Inc. (Nasdaq: PDCO) connects dental and animal health customers in North America and the U.K. to the latest products, technologies, services and innovative business solutions that enable operational and professional success. Our comprehensive portfolio, distribution network and supply chain are equaled only by our dedicated, knowledgeable people who deliver unrivaled expertise and unmatched customer service and support. Learn more: pattersoncompanies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005959/en/

Image

Posted: 06 Jan 2022 12:21 PM PST

Лариса Черникова — Одинокий волк

Posted: 06 Jan 2022 09:02 AM PST

https://youtu.be/ULMg0ZbH5tY Я, в 96 ходил на её концерт, было классно) P.S. пипец, я старый ( Написал Syisolyatin на rightmusicvideo.d3.ru / комментировать via Feedbin Starred Entries for mark.adamenko@gmail.com

-- Delivered by Feed43 service

This posting includes an audio/video/photo media file: Download Now

"Форма одежды" - все для службы и туризма (VK) Куртка Пилот черная твил

Posted: 06 Jan 2022 01:26 PM PST

Enacademic

Posted: 06 Jan 2022 02:32 PM PST

Trump's Truth Social app Could Launch Presidents Day Weekend

Posted: 06 Jan 2022 03:19 PM PST

Former president's social media app reportedly is available for pre-order before its scheduled release next month; Digital World Acquisition Corp. shares spike.

Former President Donald Trump's social media app, Truth Social, reportedly is available for pre-order before its scheduled release over the Presidents' Day holiday weekend.

The app, designed to be an alternative to Twitter, is expected to allow users to follow other people and trending topics, according to a report from Reuters citing demo photos of the app. The messages apparently will be called "truth."

Media reports said the Trump Media & Technology Group and Apple did not respond to requests for comment on the story. Reuters said a source familiar with the matter confirmed that Feb. 21 is the planned launch date of the app.

About a month ago, Digital World Acquisition Corp.  (DWACU) - Get Digital World Acquisition Corp. Report, the so-called blank check group tied to Trump's nascent media company, said it was being investigated by the U.S. Securities and Exchange Commission

Digital World said it is cooperating with the request, which also included the Financial Industry Regulatory Authority (FINRA), while describing them as "preliminary, fact-finding inquiries" linked to its merger with the former president's media and technology group.

Trump was banned from many of the major social media platforms -- including Twitter  (TWTR) - Get Twitter, Inc. Report Facebook  (MVRS) - Get Meta Report for his role in igniting the rioters that stormed the Capitol building one year ago today in a failed effort to overturn his election defeat to President Joe Biden.

Shares of Digital World Acquisition Corp. rose 17.66% Thursday to close at $68.01 and were up another 4.4% in after-hours trade.

On Wall Street, stocks ended lower amid expectations the Federal Reserve will pull back on economic stimulus sooner than expected to tamp down inflation.

SHAREHOLDER ALERT Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment Novavax, Inc. Of Class Action Lawsuit And Upcoming Deadline - NVAX

Posted: 06 Jan 2022 03:40 PM PST

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment Novavax, Inc. Of Class Action Lawsuit And Upcoming Deadline - NVAX…

FDCTech Signs Agreement With Freedom Holdings, Inc. And Its Subsidiary Carbon-Zero To Develop A Blockchain-based Carbon Credit Ecosystem

Posted: 06 Jan 2022 03:01 PM PST

Tell 2 line song lyrics below

Posted: 06 Jan 2022 09:21 AM PST

*academic2* academic2

Posted: 06 Jan 2022 01:30 PM PST

 Dynacure Receives Fast Track Designation For DYN101, An Investigational Antisense Oligonucleotide...

Posted: 06 Jan 2022 01:53 PM PST

 Dynacure Receives Fast Track Designation For DYN101, An Investigational Antisense Oligonucleotide For The Treatment Of Myotubular And Centronuclear Myopathies
together (RSS)

STRASBOURG, Pa., Jan. 6, 2022 /PRNewswire/ -- Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and life-threatening genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead product candidate, DYN101. The Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions and address significant unmet medical need.
DYN101 is currently being studied in UNITE-CNM, a multicenter Phase 1/2 clinical trial for the two most common forms of CNM, X-linked myotubular myopathy (XLMTM) and autosomal dominant CNM (ADCNM). Initial data from this ongoing ascending dose study is expected within the second half of 2022.
"CNM is a progressively debilitating life-threatening disease with no approved therapies to help. Receiving Fast Track Designation will provide us with greater access to FDA and guidance on regulatory pathways," said Leen Thielemans, Chief Development Officer of Dynacure. "We appreciate this acknowledgement by FDA of the severity of CNM, and the urgency to support this patient community with safe and effective therapies."
About Myotubular and Centronuclear Myopathies
Myotubular and Centronuclear Myopathies (CNM) are serious, rare, life-threatening disorders that affect skeletal muscles from birth. People with CNM begin experiencing muscle weakness at any time from birth to early adulthood and many patients die within the first 18 months of life. Patients who survive longer require intense medical management and nearly uninterrupted support, including permanent ventilation, brace with head support and feeding tubes. CNM derives its name based on the central location of the muscle fiber nucleus, which is an abnormal finding observed in muscle biopsies. The disease is driven by mutations in multiple genes including MTM1, DNM2 and BIN1 and Dynacure scientists have discovered a link between an increase in DNM2 protein and the direct cause of the disease  4. The three classical forms of CNM are X-linked myotubular myopathy (XLCNM), autosomal dominant CNM (ADCNM), and autosomal recessive CNM (ARCNM), which are all associated with poor prognosis. Myotubular and Centronuclear Myopathies affect an estimated 4,000 to 5,000 patients in the European Union, United States, Japan and Australia 1.
About Dynacure
Dynacure is a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drug candidates. Dynacure is developing DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein for the treatment of Myotubular and Centronuclear Myopathies, in strategic collaboration with Ionis Pharmaceuticals. Dynacure is headquartered in Strasbourg, France with a corporate office in Philadelphia, PA, USA.
For more information, please visit  www.dynacure.com .
1. Neuromuscul Disord. 2...

View original post

История одного конфликта

Posted: 06 Jan 2022 03:13 PM PST

История одного конфликта
––––––––––––––––––––––––––––––––––––––––––––––––
Конечно, это я виноват во всем, это я его спровоцировал. Написал на своей странице в ФБ:
— Как отличить еврея от беларуса. Разозлить. Беларус, если его разозлить — глупеет, еврей становится умнее.
Написал, не вкладывая никакого особого смысла. Шутка.
Он отправил мне в личку длинное послание — грязное, нацистское. В конце добавил:
— Можете пожаловаться на меня Цукеру за антисемитизм, только знайте, что антисемитизмом никогда не страдал.
Я ответил:
— Антисемиты никогда не страдают от антисемитизма. От антисемитизма страдают евреи. Антисемитам антисемитизм может даже доставлять удовольствие.
Он написал:
— Открою вам секрет. В моих жилах есть и еврейская кровь.
Я ответил:
— Видно у вас двойная система кровообращения, потому что еврейская кровь циркулирует как–то отдельно, не смешиваясь со всей остальной.
Здесь мы одновременно, как Пушкин и Дантес, забанили друг друга. Мне показалось, что он успел нажать кнопку первым.

Написал Фельдмаршал rabina1950 на microproza.d3.ru / комментировать

This posting includes an audio/video/photo media file: Download Now

academic2 together (RSS) academic2

Posted: 06 Jan 2022 01:54 PM PST

academic2 together (RSS) academic2 https://ift.tt/3zxPI0u

Новая статья: Итоги 2021 года: интернет-индустрия

Posted: 06 Jan 2022 01:00 PM PST

Конец года — самое подходящее время, чтобы взглянуть на основные события, которые произошли в сетевой среде за последние 12 месяцев. Интересного было много, поучительного не меньше. Но обо всём по порядку

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Robinhood Markets, Inc. - HOOD

Posted: 06 Jan 2022 03:09 PM PST

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Robinhood Markets, Inc. ("Robinhood" or the "Company") (NASDAQ: HOOD).  Such investors are advised to contact Robert S. Willoughby at   newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Robinhood and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On or around July 30, 2021, Robinhood conducted its initial public offering ("IPO"), offering 55 million shares of common stock to the public at a price of $38.00 per share.  Then, on October 26, 2021, Robinhood reported its third quarter 2021 financial results, revealing that its total net revenue for the period between July 1, 2021 and September 30, 2021—the same period during which the Company conducted it IPO—came in at $365 million, missing analyst estimates by nearly $73 million.  Robinhood also reported declines in its monthly active users ("MAUs"), funded accounts, assets under custody, and average revenue per user.  Robinhood also disclosed that third-quarter transaction-based revenue from cryptocurrency trading, which in the lead up to the IPO had been the bulk of the Company's revenues, was only $51 million, well below the $233 million that Robinhood earned from cryptocurrency trading in the second quarter.  Robinhood's net losses also skyrocketed from $11 million to $1.32 billion due to a $1.24 billion stock-based compensation that was tied to the stock's post-IPO performance, the initial rally in which had triggered a massive payout to Chief Executive Officer and President Vladimir Tenev and Chief Creative Officer Baiju Bhatt.  Robinhood also guided for "less than $1.8 billion" in revenue for the full year, implying a maximum 85% growth, which fell well short of analyst expectations of 111%.  On this news, Robinhood's stock price fell $4.13 per share, or nearly 10.5%, to close at $35.44 per share on October 27, 2021. 

Finally, on November 8, 2021, Robinhood disclosed that it had experienced a "data security incident" on November 3, 2021, admitting that an "unauthorized third party" had obtained email addresses for approximately five million users and the full names of a different group of approximately two million users, indicating that the attack potentially affected nearly 40% of Robinhood's MAUs.  Moreover, Robinhood reported that the additional personal information of 310 other users, including their names, dates of birth, and zip codes, were exposed, and that 10 users within that group had suffered even "more extensive" data breaches.  On this news, Robinhood's tock price fell another $3.49 per share, or 9.19%, over the following two trading sessions, to close at $34.49 per share on November 10, 2021.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT: Robert S. WilloughbyPomerantz LLP rswilloughby@pomlaw.com888-476-6529 ext. 7980

View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-robinhood-markets-inc---hood-301455932.html

SOURCE Pomerantz LLP

Чистосердечное признание

Posted: 06 Jan 2022 03:40 PM PST

Чистосердечное признание https://ift.tt/3JR1EPu

FDCTech Signs Agreement With Freedom Holdings, Inc. And Its Subsidiary Carbon-Zero To Develop A Blockchain-based Carbon Credit Ecosystem

Posted: 06 Jan 2022 03:40 PM PST

FDCTech Signs Agreement With Freedom Holdings, Inc. And Its Subsidiary Carbon-Zero To Develop A Blockchain-based Carbon Credit Ecosystem https://ift.tt/3t3cLPu

JESUS CHRIST SUPERSTAR full live 2016

Posted: 06 Jan 2022 03:40 PM PST

JESUS CHRIST SUPERSTAR full live 2016 https://ift.tt/339b34a

Image

Posted: 06 Jan 2022 12:21 PM PST

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims

Posted: 06 Jan 2022 03:17 PM PST

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exicure, Inc. ("Exicure" or the "Company") (NASDAQ: XCUR).  Such investors are advised to contact Robert S. Willoughby at   newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Exicure and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On November 15, 2021, after the market closed, Exicure disclosed in a filing with the U.S. Securities and Exchange Commission that it could not timely file its quarterly report for the period ended September 30, 2021.  Exicure explained that the Company was investigating "a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company's XCUR-FXN preclinical program for the treatment of Friedreich's ataxia." 

On this news, Exicure's stock price fell $0.30 per share, or 27.38%, to close at $1.07 per share on November 16, 2021.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT: Robert S. WilloughbyPomerantz LLP rswilloughby@pomlaw.com888-476-6529 ext. 7980

View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-301455937.html

SOURCE Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment IQIYI, Inc. And Against Goldman Sachs Group Inc. And Morgan Stanley Of Class Action Lawsuit And Upcoming Deadline - GS; MS

Posted: 06 Jan 2022 03:26 PM PST

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Goldman Sachs Group Inc. and Morgan Stanley (together, "Defendants") on behalf of investors in iQIYI, Inc. ("iQIYI" or the "Company") (IQ) - Get iQIYI Inc. Report. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-10999, is on behalf of all those investors who purchased or otherwise acquired iQIYI shares contemporaneously with Defendants' unlawful trades from March 22, 2021 through and including March 29, 2021 (the "Class Period"), pursuant to Sections 20A, 10(b), and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"), 15 U.S.C. §§ 78t-1, 78j(b), and 78t(a).

If you are a shareholder who purchased iQIYI shares during the Class Period, you have until January 31, 2022 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Archegos Capital Management ("Archegos"), a family office investment fund, was founded and run by Sung Kook Hwang ("Hwang"), a former portfolio manager of Tiger Asia Management, a hedge fund he also founded.

Goldman Sachs and Morgan Stanley are global financial services institutions that served as two of Archegos' prime brokers, helping it make trades and lending it capital in the form of margin lending. 

Archegos took big, concentrated positions in companies such as ViacomCBS Inc. ("ViacomCBS"), Vipshop Holdings Ltd., Discovery Inc., Farfetch Ltd., Gaotu Techedu, Inc., Baidu Inc., iQIYI, and Tencent Holdings Ltd. through financial instruments called "total return swaps," whereby the underlying securities are held by banks that broker the investments. 

Unbeknownst to investors and regulators, several large brokerage banks, including Defendants, each had simultaneously allowed Archegos to take on billions of dollars of exposure to volatile equities through swaps contracts, dramatically elevating the risk posed by these concentrated positions.

On March 23, 2021 ViacomCBS announced a new $3 billion offering to help fund investments in its streaming service, Paramount+, which had launched earlier in the month.

On March 25, 2021, one of Wall Street's most influential research firms, MoffettNathanson, published a report questioning ViacomCBS's value, downgrading the stock to a "sell," and setting a price target of only $55 per share, compared to the company's $85 offer. "We never, ever thought we would see Viacom[CBS] trading close to $100 per share," read the report. "Obviously, neither did ViacomCBS's management," it continued, citing the new stock offering.

In the wake of that report, ViacomCBS's stock cratered, losing more than half its value in less than a week. Indeed, by the close of trading on Friday, March 26, 2021, ViacomCBS was worth $48 per share.

This proved to be extremely problematic for Archegos, which had traded ViacomCBS on margin. Because Archegos had to maintain a certain amount of collateral to satisfy its lenders, and since the value of ViacomCBS stock drastically declined, Archegos needed enough collateral to cover, or else a margin call (where the lender can force a sell-off of the stock to bring the investor back into compliance with margin requirements), could be triggered.

On March 27, 2021, it was reported that Archegos failed to cover and, as a result, had to liquidate more than $20 billion of its leveraged equity positions on Friday, March 26, 2021.

The complaint alleges that, throughout the Class Period, Defendants sold a large number of iQIYI shares during the week of March 22, 2021, while in possession of material, non-public information.  According to subsequent media reports, Defendants unloaded large block trades consisting of shares of Archegos' doomed bets, including billions worth of iQIYI securities, late Thursday, March 25, 2021, before the Archegos story reached the public, sending iQIYI's shares into a complete tailspin.

As a result of these sales, Defendants avoided billions in losses combined.

Defendants knew, or were reckless in not knowing, that they were prohibited from trading based on this confidential market-moving information, but traded anyway, disposing to Plaintiff and other members of the Class their iQIYI shares before the news about Archegos was announced and iQIYI's shares plummeted.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT: Robert S. WilloughbyPomerantz LLP rswilloughby@pomlaw.com888-476-6529 ext. 7980

View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert--pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-iqiyi-inc-and-against-goldman-sachs-group-inc-and-morgan-stanley-of-class-action-lawsuit-and-upcoming-deadline--gs-ms-301455942.html

SOURCE Pomerantz LLP

Время брать "один до Москвы"... together (RSS) ... или...

Posted: 06 Jan 2022 01:53 PM PST


Время брать "один до Москвы"...
together (RSS)

... или спрашивать у ясеня

Ирония судьбы, или С лёгким паром!, 1976

Как скучно мы живем! В нас пропал дух авантюризма. Мы перестали лазить в окна к любимым женщинам. Мы перестали делать большие, хорошие глупости. Мы даже перестали постить часы на cinemaclock...

Тёплый ламповый ответ @pilot_pirks на южно–корейское самолётное табло.

Написал shaporin
на cinemaclock.d3.ru
/
комментировать

Чистосердечное признание

Posted: 06 Jan 2022 03:01 PM PST

Forma-odezhda.ru

Posted: 06 Jan 2022 03:01 PM PST

You should test your code for EVERY browser

Posted: 06 Jan 2022 03:01 PM PST

Брем Стокер — Козакам до сраки, вони на конях

Posted: 06 Jan 2022 03:01 PM PST

Press F to pay respect!

Posted: 06 Jan 2022 11:17 AM PST

Enacademic

Posted: 06 Jan 2022 03:01 PM PST

Купить Товары Maier Купить - Форма одежды

Posted: 06 Jan 2022 02:35 PM PST

Купить Товары Maier Купить - Форма одежды

@academic2ru posted a photo

Posted: 06 Jan 2022 03:40 PM PST

@academic2ru posted a photo https://ift.tt/3pXQb94

Image

Posted: 06 Jan 2022 12:21 PM PST

academic2.ru

Posted: 06 Jan 2022 03:01 PM PST

3 Reasons You Shouldn’t Buy the iPhone 5 in 2021 together (RSS)

Posted: 06 Jan 2022 01:53 PM PST

Купить Товары PROFARMY Купить - Форма одежды

Posted: 06 Jan 2022 02:35 PM PST

Купить Товары PROFARMY Купить - Форма одежды

 Dynacure Receives Fast Track Designation For DYN101, An Investigational Antisense Oligonucleotide...

Posted: 06 Jan 2022 01:53 PM PST

Dynacure Receives Fast Track Designation For DYN101, An Investigational Antisense Oligonucleotide For The Treatment Of Myotubular And Centronuclear Myopathies
together (RSS)

STRASBOURG, Pa., Jan. 6, 2022 /PRNewswire/ -- Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and life-threatening genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead product candidate, DYN101. The Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions and address significant unmet medical need.
DYN101 is currently being studied in UNITE-CNM, a multicenter Phase 1/2 clinical trial for the two most common forms of CNM, X-linked myotubular myopathy (XLMTM) and autosomal dominant CNM (ADCNM). Initial data from this ongoing ascending dose study is expected within the second half of 2022.
"CNM is a progressively debilitating life-threatening disease with no approved therapies to help. Receiving Fast Track Designation will provide us with greater access to FDA and guidance on regulatory pathways," said Leen Thielemans, Chief Development Officer of Dynacure. "We appreciate this acknowledgement by FDA of the severity of CNM, and the urgency to support this patient community with safe and effective therapies."
About Myotubular and Centronuclear Myopathies
Myotubular and Centronuclear Myopathies (CNM) are serious, rare, life-threatening disorders that affect skeletal muscles from birth. People with CNM begin experiencing muscle weakness at any time from birth to early adulthood and many patients die within the first 18 months of life. Patients who survive longer require intense medical management and nearly uninterrupted support, including permanent ventilation, brace with head support and feeding tubes. CNM derives its name based on the central location of the muscle fiber nucleus, which is an abnormal finding observed in muscle biopsies. The disease is driven by mutations in multiple genes including MTM1, DNM2 and BIN1 and Dynacure scientists have discovered a link between an increase in DNM2 protein and the direct cause of the disease  4. The three classical forms of CNM are X-linked myotubular myopathy (XLCNM), autosomal dominant CNM (ADCNM), and autosomal recessive CNM (ARCNM), which are all associated with poor prognosis. Myotubular and Centronuclear Myopathies affect an estimated 4,000 to 5,000 patients in the European Union, United States, Japan and Australia 1.
About Dynacure
Dynacure is a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drug candidates. Dynacure is developing DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein for the treatment of Myotubular and Centronuclear Myopathies, in strategic collaboration with Ionis Pharmaceuticals. Dynacure is headquartered in Strasbourg, France with a corporate office in Philadelphia, PA, USA.
For more information, please visit  www.dynacure.com .
1. Neuromuscul Disord. 2...

View original post

Dynacure Receives Fast Track Designation For DYN101, An Investigational Antisense Oligonucleotide For The Treatment Of Myotubular… - TheStreet
STRASBOURG, Pa., Jan. 6, 2022 /PRNewswire/ -- Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a

Image

Posted: 06 Jan 2022 12:21 PM PST

Not observed on

Posted: 06 Jan 2022 03:25 PM PST

Not observed on

Posted: 06 Jan 2022 03:25 PM PST

Товары Duraflex - Форма одежды

Posted: 06 Jan 2022 02:35 PM PST

Товары Duraflex - Форма одежды

DraftKings Launches In New York This Weekend

Posted: 06 Jan 2022 03:20 PM PST

The mobile betting application will finally go live on Saturday.

Mobile sports betting app DraftKings Mobile Sportsbook will finally go live in New York on Saturday, much to the delight of New York City citizens who were tired of taking the PATH train to Hoboken, New Jersey to place bets on their phone.

The Boston-based company was founded in 2012, and it allows users to make bets, and if they're lucky win money, on all five major American sports (MLB, the NHL, the NFL, the NBA and the PGA), as well as everything from Nascar to MMA games and fantasy sports-based games. 

For the first several years of its existence, DraftKings focused on fantasy sports games, due to legal restrictions against sports gambling in all states except Nevada. 

But in in May 2018, the Professional and Amateur Sports Protection Act of 1992 was declared unconstitutional by the Supreme Court of the United States, and later that year, DraftKings launched its first legal mobile and online sportsbook company in New Jersey. 

Many states slowly began allowing betting afterwards, but the Garden State was the first to enthusiastically embrace betting via mobile phone. 

The New Jersey Division of Gaming Enforcement employed the company GeoComply to ensure all bettors comply with the state's geographical requirements and to prevent any virtual private networks-related funny business.

This all caused a bit of consternation amongst sports fans in the Empire City, as no New Yorker ever likes to feel as though New Jersey has one up on them. 

But on April 6 of last year, New York state legislators passed a state budget bill that would allow for online and mobile sports betting, and regulators such as the New York State Gaming Commission spent the rest of the year finalizing the official rules for mobile betting.

The service will be restricted to ages 21 and over, and will prohibit betting on any New York college game. The bets will will include pre-match and in-game markets, including same game parlays.

"We are excited to finally be able to offer millions of passionate New York sports fans the top rated DraftKings mobile and online Sportsbook," said Jason Robins, CEO, co-founder and chairman of the board, DraftKings in a statement. 

"We want to extend a special thanks to Governor Hochul, Senator Addabbo, Assemblyman Pretlow, the New York Gaming Commission along with the tireless efforts of our dedicated DraftKings team for making this a reality."

New York is home to 10 professional sports team and, as anyone who has been near a subway during the Superbowl or a play-off game can attest, millions of enthusiastic fans, and this launch comes just in time for Sunday's match-up of the New York Jets and the Buffalo Bills.

This launch will have broader implications outside of New York City, according to Ken Hershman, co-founder and CEO Champion Gaming

"One immediate effect will be that a number of other States, both contiguous and not, will need to quickly follow suit in opening their States to legalized sports wagering if they haven't already," he said. "But also, as we have seen with the democratization of the finance industry, New York will likely lead in the evolution of new and more sophisticated tools, news and information for the sports wagering community writ large."

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Medallion Financial Corp. - MFIN

Posted: 06 Jan 2022 03:16 PM PST

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Medallion Financial Corp. ("Medallion" or the "Company")  (MFIN) - Get Medallion Financial Corp. Report. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Medallion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action] 

On December 29, 2021, the U.S. Securities and Exchange Commission ("SEC") filed a complaint alleging that Medallion and certain of its corporate officers had engaged in an unlawful scheme in an effort to reverse the Company's declining stock price. The charges in the SEC complaint include violations of antifraud, books and records, internal controls, and anti-touting provisions of the federal securities laws.

On this news, Medallion's stock price fell $1.78 per share, or 21.07%, to close at $6.67 per share on December 29, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT: Robert S. WilloughbyPomerantz LLP rswilloughby@pomlaw.com888-476-6529 ext. 7980

View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-medallion-financial-corp---mfin-301455855.html

SOURCE Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Generation Bio Co. - GBIO

Posted: 06 Jan 2022 03:26 PM PST

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Generation Bio Co. ("Generation" or the "Company")  (GBIO) . Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Generation Bio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action] 

On or around June 11, 2020, Generation conducted its initial public offering ("IPO"), selling 12,105,263 shares of common stock priced at $19.00 per share. Then, on December 14, 2021, Generation issued a press release that "provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A, as well as an update on the development of its non-viral genetic medicine platform. GeneratioN's proprietary genetic medicine technology comprises a closed-ended DNA (ceDNA) delivered via a novel, cell-targeted lipid nanoparticle (ctLNP)." Generation disclosed results that showed that in mice, ceDNA generated peak mean human factor VIII expression of 205% of normal at 2.0 mg/kg, and advised that "[a]dditional optimization is needed to translate the improvement in potency and reduction in variability observed in mice to [non-human primates], and to support nomination of a development candidate for the company's hemophilia A program[.]"

On this news, Generation's stock price fell $7.91 per share, or 56.91%, to close at $7.91 per share on December 14, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT: Robert S. WilloughbyPomerantz LLP rswilloughby@pomlaw.com888-476-6529 ext. 7980

View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-generation-bio-co---gbio-301455873.html

SOURCE Pomerantz LLP

Don't have Telegram yet?

Posted: 06 Jan 2022 01:30 PM PST

Don't have Telegram yet?

Don't have Telegram yet? Try it now!

Don't have Telegram yet? Try it now!
Read more...

ZELENYIKOT и "зелёные человечки" в гостях у Шихман

Posted: 06 Jan 2022 03:27 PM PST

https://www.youtube.com/watch?v=q695FdZeg6s&ab_channel=%D0%90%D0%BF%D0%BE%D0%B3%D0%BE%D0%B2%D0%BE%D1%80%D0%B8%D1%82%D1%8C%3F

В гостях у Ирины Шихман – российский популяризатор космонавтики, блогер и писатель Виталий Егоров. Сегодня поговорим о внеземных цивилизациях, НЛО, пришельцах, инопланетянах. Что знает об этом наука?

00:00  — Вступление
00:26 — Что такое Парадокс Ферми?
02:41 — О проектах по поиску внеземных цивилизаций
14:23 — Кто спонсирует проекты по поиску инопланетной жизни?
17:12 — Можно ли «услышать» инопланетян?
26:52 — Каким образом можно подать сигнал в космос?
31:00 — О космических мегаструктурах, сфера Дайсона и самом сложном космическом телескопе России
37:52 — Какими могут быть другие цивилизации?
45:22 — Сколько солнечных систем и галактик во вселенной?
47:02  — Какова вероятность существования других цивилизаций?
51:30 — О золотой пластинке «Вояджера»
55:37  — Уравнение Дрейка: поиск внеземного разума
59:56 — Откуда появляются фотографии и видео с НЛО?
1:13:55 — О тайне происхождения Стоунхенджа и его аналогов

Написал ecort на astronautics.d3.ru / комментировать

At least he died doing what he loved...

Posted: 06 Jan 2022 11:10 AM PST

Просим прощения Silent Stats v10 не предназначен для работы с другими каналами, и поэтому он покинет его

Posted: 06 Jan 2022 01:26 PM PST

Просим прощения Silent Stats v10 не предназначен для работы с другими каналами, и поэтому он покинет его

Просим прощения
Silent Stats v10 не предназначен для работы с другими каналами, и поэтому он покинет его...

Bruh WTF

Posted: 06 Jan 2022 03:40 PM PST

Bruh WTF https://ift.tt/32O5eJS

Image

Posted: 06 Jan 2022 12:21 PM PST

Комментариев нет:

Отправить комментарий

webmention

Infocourt

News digest

Together digest